The Justice Department is requesting documents about Jazz Pharmaceuticals’ support of charitable organizations providing assistance to Medicare patients, the Dublin-based company said May 10.
In a filing with the Securities and Exchange Commission, Jazz revealed it received a documents subpoena from the U.S. Attorney’s Office for the District of Massachusetts in May.
The subpoena also seeks documents related to Jazz’s provision of financial assistance to Medicare patients using Jazz’s narcolepsy drug Xyrem (sodium oxybate), the company’s top-selling product.
Jazz said it intends to cooperate with the subpoena. It also said it’s possible that the company could “incur significant costs in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.